Heart and Blood Diseases

All Conditions

Heart Failure

Heart Diseases

Antihypertensive Agents

All Drugs and Chemicals

Vasoconstrictor Agents

Valsartan

Sacubitril and valsartan sodium hydrate drug combination

Angiotensin II

Giapreza

Angiotensinogen

Angiotensin II Type 1 Receptor Blockers

Angiotensin Receptor Antagonists

Sacubitril-valsartan administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).

Valsartan administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)

Administered orally twice daily at a maximally tolerate dose (max dose 97mg/103mg twice daily).

Sacubitril-valsartan

Administered orally twice daily at a maximally tolerate dose (max dose 160mg twice daily)

Massey Cancer Control DWG

Massey CTO Operations Managers

Massey CPC DWG

Wendy Bottinor, MD

To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.

The current study will test the hypothesis that among adult age survivors of cancer diagnosed at age \< 39 years treatment of Stage B heart failure with sacubitril-valsartan is feasible and safe.

Cardiac magnetic resonance studies will be de-identified and assigned a study number. The identification key will not be available to cardiac magnetic resonance readers so that they are blinded to treatment allocation

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

There are no plans to make individual participant data available to other researchers at this time.

Number of participants screened for the clinical trial.

Number of participants enrolled on the trial

Number of participants that complete therapy

Number of deaths while on study due to cardiac event

Number of deaths while on study due to non-cardiac events

By the number of Adverse events at 30 days

By the number of Adverse events at 60 days

By the number of Adverse events at 90 days

By determining number of participants with interval change utilizing a 6-minute walk test distance

By number of participants with cardiovascular magnetic resonance imaging assessment change in cardiac fibrosis burden.

By number of participants with cardiovascular magnetic resonance imaging assessment change in microvascular perfusion.

By number of participants with cardiovascular magnetic resonance imaging assessment change in arterial stiffness/4D flow.

By number of participants with cardiovascular magnetic resonance imaging assessment change in left ventricular ejection fraction.

By number of participants with cardiovascular magnetic resonance imaging assessment change in change in left ventricular strain.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan	NCT05194111	Heart Failure Heart Dysfuncti...	Sacubitril-vals... Valsartan	18 Years - 120 Years	Virginia Commonwealth University
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan	NCT05194111	Heart Failure Heart Dysfuncti...	Sacubitril-vals... Valsartan	18 Years - 120 Years	Virginia Commonwealth University

Spots Global Cancer Trial Database for heart dysfunction